[Beta adrenolytic and hemodynamic effects of dl (hydroxy 2't-butylamino 3' propyloxy) 8-thiochromane (S 2395)].
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D000605:Amino Alcohols / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D000818:Animals; D001578:Benzopyrans / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D001794:Blood Pressure / Q000187:drug effects; D001986:Bronchial Spasm / Q000188:drug therapy; D004285:Dogs; D005260:Female; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006943:Hyperglycemia / Q000188:drug therapy; D007545:Isoproterenol / Q000037:antagonists & inhibitors; D007928:Lethal Dose 50; D008297:Male; D011437:Propylamines / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D013440:Sulfides / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D013610:Tachycardia / Q000188:drug therapy
D000319:Adrenergic beta-Antagonists; D000605:Amino Alcohols; D001578:Benzopyrans; D011437:Propylamines; D013440:Sulfides; D007545:Isoproterenol
Effets adrénolytiques bêta et hémodynamiques du dl (hydroxy 2't-butylamino 3' propyloxy) 8-thiochromane (S 2395.